Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
561 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Neuropathic Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2016, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape. Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 27, 29, 1, 119, 21 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively. Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 8 Neuropathic Pain Overview 9 Therapeutics Development 10 Neuropathic Pain - Therapeutics under Development by Companies 12 Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 22 Neuropathic Pain - Pipeline Products Glance 24 Neuropathic Pain - Products under Development by Companies 28 Neuropathic Pain - Products under Investigation by Universities/Institutes 42 Neuropathic Pain - Companies Involved in Therapeutics Development 44 Neuropathic Pain - Therapeutics Assessment 165 Drug Profiles 188 Neuropathic Pain - Dormant Projects 491 Neuropathic Pain - Discontinued Products 516 Neuropathic Pain - Product Development Milestones 524 Appendix 534
List of Tables
Number of Products under Development for Neuropathic Pain, H2 2016 36 Number of Products under Development for Neuropathic Pain - Comparative Analysis, H2 2016 37 Number of Products under Development by Companies, H2 2016 38 Number of Products under Development by Companies, H2 2016 (Contd..1) 39 Number of Products under Development by Companies, H2 2016 (Contd..2) 40 Number of Products under Development by Companies, H2 2016 (Contd..3) 41 Number of Products under Development by Companies, H2 2016 (Contd..4) 42 Number of Products under Development by Companies, H2 2016 (Contd..5) 43 Number of Products under Development by Companies, H2 2016 (Contd..6) 44 Number of Products under Development by Companies, H2 2016 (Contd..7) 45 Number of Products under Development by Companies, H2 2016 (Contd..8) 46 Number of Products under Development by Companies, H2 2016 (Contd..9) 47 Number of Products under Investigation by Universities/Institutes, H2 2016 48 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 49 Comparative Analysis by Late Stage Development, H2 2016 50 Comparative Analysis by Clinical Stage Development, H2 2016 51 Comparative Analysis by Early Stage Development, H2 2016 52 Comparative Analysis by Unknown Stage Development, H2 2016 53 Products under Development by Companies, H2 2016 54 Products under Development by Companies, H2 2016 (Contd..1) 55 Products under Development by Companies, H2 2016 (Contd..2) 56 Products under Development by Companies, H2 2016 (Contd..3) 57 Products under Development by Companies, H2 2016 (Contd..4) 58 Products under Development by Companies, H2 2016 (Contd..5) 59 Products under Development by Companies, H2 2016 (Contd..6) 60 Products under Development by Companies, H2 2016 (Contd..7) 61 Products under Development by Companies, H2 2016 (Contd..8) 62 Products under Development by Companies, H2 2016 (Contd..9) 63 Products under Development by Companies, H2 2016 (Contd..10) 64 Products under Development by Companies, H2 2016 (Contd..11) 65 Products under Development by Companies, H2 2016 (Contd..12) 66 Products under Development by Companies, H2 2016 (Contd..13) 67 Products under Investigation by Universities/Institutes, H2 2016 68 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 69 Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H2 2016 70 Neuropathic Pain - Pipeline by AbbVie Inc, H2 2016 71 Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H2 2016 72 Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H2 2016 73 Neuropathic Pain - Pipeline by Adynxx Inc, H2 2016 74 Neuropathic Pain - Pipeline by Aevi Genomic Medicine Inc, H2 2016 75 Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2 2016 76 Neuropathic Pain - Pipeline by Amura Holdings Ltd, H2 2016 77 Neuropathic Pain - Pipeline by AnaBios Corp, H2 2016 78 Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H2 2016 79 Neuropathic Pain - Pipeline by AngioChem Inc, H2 2016 80 Neuropathic Pain - Pipeline by APT Therapeutics Inc, H2 2016 81 Neuropathic Pain - Pipeline by Aquilus Pharmaceuticals Inc, H2 2016 82 Neuropathic Pain - Pipeline by Araim Pharmaceuticals Inc, H2 2016 83 Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2016 84 Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp, H2 2016 85 Neuropathic Pain - Pipeline by Astellas Pharma Inc, H2 2016 86 Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2016 87 Neuropathic Pain - Pipeline by BCI Pharma, H2 2016 88 Neuropathic Pain - Pipeline by Biogen Inc, H2 2016 89 Neuropathic Pain - Pipeline by BioLineRx Ltd, H2 2016 90 Neuropathic Pain - Pipeline by Biomar Microbial Technologies, H2 2016 91 Neuropathic Pain - Pipeline by Bionomics Ltd, H2 2016 92 Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2016 93 Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H2 2016 94 Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H2 2016 95 Neuropathic Pain - Pipeline by Catalyst Biosciences Inc, H2 2016 96 Neuropathic Pain - Pipeline by Cavion LLC, H2 2016 97 Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 98 Neuropathic Pain - Pipeline by Cerecor Inc, H2 2016 99 Neuropathic Pain - Pipeline by Chromocell Corp, H2 2016 100 Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H2 2016 101 Neuropathic Pain - Pipeline by CLL Pharma SA, H2 2016 102 Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H2 2016 103 Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 104 Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H2 2016 105 Neuropathic Pain - Pipeline by Cytogel Pharma LLC, H2 2016 106 Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 107 Neuropathic Pain - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 108 Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H2 2016 109 Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H2 2016 110 Neuropathic Pain - Pipeline by Eisai Co Ltd, H2 2016 111 Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2016 112 Neuropathic Pain - Pipeline by Endece LLC, H2 2016 113 Neuropathic Pain - Pipeline by Evec Inc, H2 2016 114 Neuropathic Pain - Pipeline by Genecode AS, H2 2016 115 Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 116 Neuropathic Pain - Pipeline by Glialogix Inc, H2 2016 117 Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2016 118 Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016 119 Neuropathic Pain - Pipeline by Hydra Biosciences Inc, H2 2016 120 Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc, H2 2016 121 Neuropathic Pain - Pipeline by Inpellis Inc, H2 2016 122 Neuropathic Pain - Pipeline by Integral Molecular Inc, H2 2016 123 Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc, H2 2016 124 Neuropathic Pain - Pipeline by iX Biopharma Ltd, H2 2016 125 Neuropathic Pain - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 126 Neuropathic Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 127 Neuropathic Pain - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2016 128 Neuropathic Pain - Pipeline by Johnson & Johnson, H2 2016 129 Neuropathic Pain - Pipeline by Kareus Therapeutics SA, H2 2016 130 Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H2 2016 131 Neuropathic Pain - Pipeline by Kolon Life Science Inc, H2 2016 132 Neuropathic Pain - Pipeline by KPI Therapeutics Inc, H2 2016 133 Neuropathic Pain - Pipeline by Laboratorios Del Dr Esteve SA, H2 2016 134 Neuropathic Pain - Pipeline by Lexicon Pharmaceuticals Inc, H2 2016 135 Neuropathic Pain - Pipeline by Lohocla Research Corp, H2 2016 136 Neuropathic Pain - Pipeline by Lpath Inc, H2 2016 137 Neuropathic Pain - Pipeline by Mapi Pharma Ltd, H2 2016 138 Neuropathic Pain - Pipeline by Medestea Research & Production SpA, H2 2016 139 Neuropathic Pain - Pipeline by Medifron DBT Co Ltd, H2 2016 140 Neuropathic Pain - Pipeline by Medisyn Technologies Inc, H2 2016 141 Neuropathic Pain - Pipeline by Medy-Tox Inc, H2 2016 142 Neuropathic Pain - Pipeline by Merck & Co Inc, H2 2016 143 Neuropathic Pain - Pipeline by Nanomerics Ltd, H2 2016 144 Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 145 Neuropathic Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2016 146 Neuropathic Pain - Pipeline by NeuroCycle Therapeutics GmbH, H2 2016 147 Neuropathic Pain - Pipeline by NeuroMax, H2 2016 148 Neuropathic Pain - Pipeline by NeurOp Inc, H2 2016 149 Neuropathic Pain - Pipeline by Newron Pharmaceuticals SpA, H2 2016 150 Neuropathic Pain - Pipeline by Nippon Chemiphar Co Ltd, H2 2016 151 Neuropathic Pain - Pipeline by NoNO Inc, H2 2016 152 Neuropathic Pain - Pipeline by Novaremed Ltd, H2 2016 153 Neuropathic Pain - Pipeline by Novartis AG, H2 2016 154 Neuropathic Pain - Pipeline by NsGene A/S, H2 2016 155 Neuropathic Pain - Pipeline by Omeros Corp, H2 2016 156 Neuropathic Pain - Pipeline by Orion Oyj, H2 2016 157 Neuropathic Pain - Pipeline by Patagonia Pharmaceuticals LLC, H2 2016 158 Neuropathic Pain - Pipeline by PeriphaGen Inc, H2 2016 159 Neuropathic Pain - Pipeline by Pfizer Inc, H2 2016 160 Neuropathic Pain - Pipeline by Pharmaleads SA, H2 2016 161 Neuropathic Pain - Pipeline by PharmEste Srl, H2 2016 162 Neuropathic Pain - Pipeline by Phosphagenics Ltd, H2 2016 163 Neuropathic Pain - Pipeline by Prismic Pharmaceuticals Inc, H2 2016 164 Neuropathic Pain - Pipeline by RaQualia Pharma Inc, H2 2016 165 Neuropathic Pain - Pipeline by Re-Pharm Ltd, H2 2016 166 Neuropathic Pain - Pipeline by Relmada Therapeutics Inc, H2 2016 167 Neuropathic Pain - Pipeline by Revance Therapeutics Inc, H2 2016 168 Neuropathic Pain - Pipeline by Saniona AB, H2 2016 169 Neuropathic Pain - Pipeline by Scilex Pharmaceuticals Inc, H2 2016 170 Neuropathic Pain - Pipeline by Shionogi & Co Ltd, H2 2016 171 Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 172 Neuropathic Pain - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 173 Neuropathic Pain - Pipeline by Spherium Biomed SL, H2 2016 174 Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc, H2 2016 175 Neuropathic Pain - Pipeline by Syntrix Biosystems Inc, H2 2016 176 Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 177 Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 178 Neuropathic Pain - Pipeline by Theranexus SAS, H2 2016 179 Neuropathic Pain - Pipeline by Theravasc Inc, H2 2016 180 Neuropathic Pain - Pipeline by Toray Industries Inc, H2 2016 181 Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Ltd, H2 2016 182 Neuropathic Pain - Pipeline by Trevena Inc, H2 2016 183 Neuropathic Pain - Pipeline by Trigemina Inc, H2 2016 184 Neuropathic Pain - Pipeline by Virobay Inc, H2 2016 185 Neuropathic Pain - Pipeline by VistaGen Therapeutics Inc, H2 2016 186 Neuropathic Pain - Pipeline by Vitality Biopharma Inc, H2 2016 187 Neuropathic Pain - Pipeline by Yuhan Corp, H2 2016 188 Neuropathic Pain - Pipeline by Yungjin Pharm Co Ltd, H2 2016 189 Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 190 Assessment by Monotherapy Products, H2 2016 191 Assessment by Combination Products, H2 2016 192 Number of Products by Stage and Target, H2 2016 194 Number of Products by Stage and Mechanism of Action, H2 2016 202 Number of Products by Stage and Route of Administration, H2 2016 211 Number of Products by Stage and Molecule Type, H2 2016 213 Neuropathic Pain - Dormant Projects, H2 2016 517 Neuropathic Pain - Dormant Projects (Contd..1), H2 2016 518 Neuropathic Pain - Dormant Projects (Contd..2), H2 2016 519 Neuropathic Pain - Dormant Projects (Contd..3), H2 2016 520 Neuropathic Pain - Dormant Projects (Contd..4), H2 2016 521 Neuropathic Pain - Dormant Projects (Contd..5), H2 2016 522 Neuropathic Pain - Dormant Projects (Contd..6), H2 2016 523 Neuropathic Pain - Dormant Projects (Contd..7), H2 2016 524 Neuropathic Pain - Dormant Projects (Contd..8), H2 2016 525 Neuropathic Pain - Dormant Projects (Contd..9), H2 2016 526 Neuropathic Pain - Dormant Projects (Contd..10), H2 2016 527 Neuropathic Pain - Dormant Projects (Contd..11), H2 2016 528 Neuropathic Pain - Dormant Projects (Contd..12), H2 2016 529 Neuropathic Pain - Dormant Projects (Contd..13), H2 2016 530 Neuropathic Pain - Dormant Projects (Contd..14), H2 2016 531 Neuropathic Pain - Dormant Projects (Contd..15), H2 2016 532 Neuropathic Pain - Dormant Projects (Contd..16), H2 2016 533 Neuropathic Pain - Dormant Projects (Contd..17), H2 2016 534 Neuropathic Pain - Dormant Projects (Contd..18), H2 2016 535 Neuropathic Pain - Dormant Projects (Contd..19), H2 2016 536 Neuropathic Pain - Dormant Projects (Contd..20), H2 2016 537 Neuropathic Pain - Dormant Projects (Contd..21), H2 2016 538 Neuropathic Pain - Dormant Projects (Contd..22), H2 2016 539 Neuropathic Pain - Dormant Projects (Contd..23), H2 2016 540 Neuropathic Pain - Dormant Projects (Contd..24), H2 2016 541 Neuropathic Pain - Discontinued Products, H2 2016 542 Neuropathic Pain - Discontinued Products (Contd..1), H2 2016 543 Neuropathic Pain - Discontinued Products (Contd..2), H2 2016 544 Neuropathic Pain - Discontinued Products (Contd..3), H2 2016 545 Neuropathic Pain - Discontinued Products (Contd..4), H2 2016 546 Neuropathic Pain - Discontinued Products (Contd..5), H2 2016 547 Neuropathic Pain - Discontinued Products (Contd..6), H2 2016 548 Neuropathic Pain - Discontinued Products (Contd..7), H2 2016 549
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
